The Ahmedabad-based Cadila Pharmaceuticals (CPL) will be launching the first intravenous (IV) dosage form of the anti-ulcerant drug rabeprazole sodium in the world. The company, which introduced the solid dosage of the drug, Rabeloc, for the first time in the country in 2002, has received the DCGI approval to manufacture and market the IV formulation recently.
Rabeprazole sodium, currently the most advanced anti-ulcerant for duodenal ulcers, gastro ulcers and heartburn (gastroesophageal reflux disease -GERD), with the IV dosage form is advised for severe and life-threatening ulcer where patient is having upper gastro-intestinal bleeding. The company will be launching the product under the brand name Rabeloc IV shortly in India.
In the gastro segment, Cadila Pharma is currently a leading player with brands such as Aciloc, Lancus, Domperon, Olit, Morsat and others, which enjoy a significant share of the Rs 445-crore anti-ulcerant market. The company has conducted extensive multicentric clinical trials on rabeprazole at institutions like AIIMS (All India Institute of Medical Sciences, New Delhi), LTMC (Lokmanya Tilak Medical College, Mumbai), Sion Hospital, Mumbai and VS Hospital (Vadilal Sarabhai Hospital), Ahmedabad.
|
